Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PEPG | US
-0.05
-3.14%
Healthcare
Biotechnology
30/06/2024
24/04/2026
1.54
1.57
1.60
1.53
PepGen Inc. a clinical-stage biotechnology company focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51 an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1 an EDO peptide-conjugated PMO which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1 as well as EDO therapeutic candidates such as PGN-EDO53 PGN-EDO45 and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
53.8%1 month
202.4%3 months
149.6%6 months
130.2%-
-
1.88
0.13
0.10
-3.11
-
-
-94.36M
50.19M
50.19M
-
-
-
-
-58.97
7.73
5.64
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.27
Range1M
4.05
Range3M
5.82
Rel. volume
0.24
Price X volume
886.94K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| OKYO Pharma Limited | OKYO | Biotechnology | 1.61 | 54.48M | 1.26% | n/a | -107.88% |
| Rani Therapeutics Holdings Inc. Class A Common Stock | RANI | Biotechnology | 0.9389 | 54.33M | 2.56% | n/a | 1243.32% |
| LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.8 | 52.37M | 10.34% | n/a | 118.63% |
| 22nd Century Group Inc | XXII | Biotechnology | 1.66 | 52.18M | -2.92% | n/a | -1072.15% |
| Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 1.28 | 51.37M | 1.59% | n/a | 2.71% |
| Gain Therapeutics Inc. Common Stock | GANX | Biotechnology | 1.97 | 50.30M | 4.23% | n/a | 6.85% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 14.3 | 48.75M | 2.36% | n/a | 3.14% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 5.91 | 47.06M | -3.90% | n/a | -6472.02% |
| Minerva Neurosciences Inc | NERV | Biotechnology | 6.575 | 45.98M | -3.73% | n/a | -194.60% |
| TPST | TPST | Biotechnology | 1.79 | 45.12M | -0.56% | n/a | 119.58% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.11 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.88 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 149.55 | 72.80 | Riskier |
| Debt to Equity | 0.13 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 50.19M | 3.66B | Emerging |